We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01602367
First Posted: May 21, 2012
Last Update Posted: October 12, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Bristol-Myers Squibb
May 17, 2012
May 21, 2012
October 12, 2015
July 2012
November 2012   (Final data collection date for primary outcome measure)
The dose-dependent trend among doses of BMS-823778 and placebo by assessing the change from baseline in 24-hour ambulatory diastolic blood pressure following 12 weeks of double-blind treatment [ Time Frame: At Day -7 (baseline) and Week 12 ]
Same as current
Complete list of historical versions of study NCT01602367 on ClinicalTrials.gov Archive Site
  • Change in 24-hour ambulatory systolic blood pressure (SBP)(evaluation of the dose-dependent trend) [ Time Frame: At Day -7 (baseline) and Week 12 ]
  • Change in 24-hour ambulatory diastolic blood pressure (DBP) [ Time Frame: At Day -7 (baseline) and Week 12 ]
  • Change in 24-hour ambulatory SBP [ Time Frame: At Day -7 (baseline) and Week 12 ]
  • Change in ambulatory daytime and nighttime DBP [ Time Frame: At Day -7 (baseline) and Week 12 ]
  • Change in ambulatory daytime and nighttime SBP [ Time Frame: At Day -7 (baseline) and Week 12 ]
  • Change in seated DBP [ Time Frame: At Day -7 (baseline) and Week 12 ]
  • Change in seated SBP [ Time Frame: At Day -7 (baseline) and Week 12 ]
Same as current
Not Provided
Not Provided
 
Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2B Trial to Evaluate the Safety and Efficacy of BMS-823778 in Overweight and Obese Subjects With Inadequately Controlled Hypertension
The purpose of this study is to determine whether BMS-823778 is safe and effective in the treatment of hypertension in overweight and obese patients.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Hypertension
  • Drug: BMS-823778
    Capsules, Oral, 2 mg, Once daily, 12 weeks
  • Drug: BMS-823778
    Capsules, Oral, 6 mg, Once daily, 12 weeks
  • Drug: BMS-823778
    Capsules, Oral, 15 mg, Once daily, 12 weeks
  • Drug: Placebo matching with BMS-823778
    Capsules, Oral, 0 mg, Once daily, 12 weeks
  • Experimental: Arm 1: BMS-823778 (2mg)
    Intervention: Drug: BMS-823778
  • Experimental: Arm2: BMS-823778 (6mg)
    Intervention: Drug: BMS-823778
  • Experimental: Arm 3: BMS-823778 (15mg)
    Intervention: Drug: BMS-823778
  • Experimental: Arm4: Placebo
    Intervention: Drug: Placebo matching with BMS-823778
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
7
November 2012
November 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Qualifying seated blood pressure between ≥90 and ≤105 mmHg diastolic AND ≤155 mmHg systolic
  • Mean 24-hour diastolic blood pressure ≥85 mmHg
  • Body mass index (BMI) ≥27 kg/m2
  • If receiving an oral anti-hyperglycemic medication or a cholesterol lowering medication, receiving a stable dose for at least 6 weeks

Exclusion Criteria:

  • History of Cushing's disease or syndrome, or Addison's disease
  • Glycosylated hemoglobin (HbA1c) ≥10%
  • Cerebrovascular insult, unstable angina, or myocardial infarction (MI) within 6 months
  • History of impaired renal or hepatic function
  • BMI ≥50 kg/m2
  • Any injectable antihyperglycemic agent (such as insulin) within 16 weeks
  • Currently receiving more than one class of antihypertensive agents within 4 weeks
  • Daily use of nonsteroidal anti-inflammatory agents within 1 week
  • Use of androgen medications, including topical preparations, within 6 weeks
  • Diagnosis or history of breast cancer
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Colombia,   Hungary,   Puerto Rico,   Sweden,   United States
Argentina,   Mexico
 
NCT01602367
MB121-008
2012‐000509‐54 ( EudraCT Number )
No
Not Provided
Not Provided
Bristol-Myers Squibb
Bristol-Myers Squibb
Not Provided
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Bristol-Myers Squibb
September 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP